|Bid||31.65 x 1400|
|Ask||31.70 x 1300|
|Day's Range||30.73 - 31.85|
|52 Week Range||25.15 - 300.00|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Aurora Cannabis missed its own revenue estimates for the fourth quarter, but Chief Corporate Officer Cam Battley explains why it wasn't all bad news.
Cannabis ETFs the ETFMG Alternative Harvest ETF and the Horizons Marijuana Life Sciences Index ETF were up 0.7% and 0.4%, respectively, at 2:15 PM today.
After Tilray's second-quarter earnings, Benchmark reduced its target price to $80 from $120. Cowen and Company reduced the target price to $60 from $150.
The S&P; 500 Index and the DJIA fell 0.3% and 0.1%, respectively, today. However, the cannabis ETFs and the majority of the cannabis stocks were trading in the green.
Despite growing sales and wider legalization, many pot stocks have been insanely volatile as Wall Street and investors try to wrap their heads around the marijuana industry. So should you think about buying "cheap" Aurora Cannabis (ACB) Stock before Q4 earnings?
Minnesota hasn’t been able to come up with a legalization decision yet. However, the state decided to learn how the public feels about legalization.
Cowen analyst Vivien Azer slashed her price target for Tilray by 60%. So why did the pot stock jump on the news?
(Bloomberg) -- The street’s biggest bull on Tilray Inc. is feeling significantly less bullish, slashing her price target on the pot stock by 60%.Vivien Azer at Cowen & Co. cut her 12-month target to $60 from $150, but still believes the stock’s recent weakness is a buying opportunity. Tilray jumped as much as 17% Tuesday, heading for its biggest gain since January. The stock has lost about 90% from the intraday high of $300 it reached in September 2018.The Canadian cannabis landscape “has been challenging over the last few months, as too few stores, supply shortages and a lack of novel products have hampered category development,” Azer wrote in a note published Tuesday. “We would argue that TLRY has been the most impacted by weak industry supply as its asset-light model was initially overly reliant on third-party supply.”She maintained her outperform rating, however, citing Tilray’s proactive moves to address capacity constraints, its strong position to enter the U.S. CBD market and growing international opportunities. She also believes the Canadian industry will work out its problems eventually, becoming a C$12 billion market by 2025.With Azer’s lower price target, Michael Hickey at Benchmark Co. becomes Tilray’s biggest bull with an $80 target.(Adds stock move in second paragraph.)To contact the reporter on this story: Kristine Owram in Toronto at email@example.comTo contact the editors responsible for this story: Brad Olesen at firstname.lastname@example.org, Steven FrommFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.